RESUMEN
The pharmacokinetics, mass balance, and metabolite profiles of faldaprevir, a selective peptide-mimetic hepatitis C virus NS3/NS4 protease inhibitor, were assessed at steady state in 7 healthy male subjects. Subjects received oral doses of 480 mg faldaprevir on day 1, followed by 240 mg faldaprevir on days 2 to 8 and 10 to 15. [14C]faldaprevir (240 mg containing 100 µCi) was administered on day 9. Blood, urine, feces, and saliva samples were collected at intervals throughout the study. Metabolite profiling was performed using radiochromatography, and metabolite identification was conducted using liquid chromatography-tandem mass spectrometry. The overall recovery of radioactivity was high (98.8%), with the majority recovered from feces (98.7%). There was minimal radioactivity in urine (0.113%) and saliva. Circulating radioactivity was predominantly confined to plasma with minimal partitioning into red blood cells. The terminal half-life of radioactivity in plasma was approximately 23 h with no evidence of any long-lasting metabolites. Faldaprevir was the predominant circulating form, accounting for 98 to 100% of plasma radioactivity from each subject. Faldaprevir was the only drug-related component detected in urine. Faldaprevir was also the major drug-related component in feces, representing 49.8% of the radioactive dose. The majority of the remainder of radioactivity in feces (41% of the dose) was accounted for in almost equal quantities by 2 hydroxylated metabolites. The most common adverse events were nausea, diarrhea, and constipation, all of which were related to study drug. In conclusion, faldaprevir is predominantly excreted in feces with negligible urinary excretion.
Asunto(s)
Hepacivirus/efectos de los fármacos , Oligopéptidos/farmacología , Oligopéptidos/farmacocinética , Inhibidores de Proteasas/farmacología , Inhibidores de Proteasas/farmacocinética , Tiazoles/farmacología , Tiazoles/farmacocinética , Adolescente , Adulto , Ácidos Aminoisobutíricos , Humanos , Leucina/análogos & derivados , Masculino , Persona de Mediana Edad , Oligopéptidos/efectos adversos , Oligopéptidos/orina , Prolina/análogos & derivados , Inhibidores de Proteasas/efectos adversos , Inhibidores de Proteasas/orina , Quinolinas , Tiazoles/efectos adversos , Tiazoles/orina , Adulto JovenRESUMEN
Hepatocytes provide an integrated model to study drug metabolism and disposition. As a result of a loss of polarity or a significant decrease in the expression of enzymes and transporters, suspended and sandwich-cultured hepatocytes have limitations in determining hepatocellular drug concentrations. Underprediction of the extent of glucuronidation is also a concern for these hepatocyte models. Faldaprevir is a hepatitis C virus protease inhibitor in late-stage development that has demonstrated significant liver enrichment in in vivo rat models based on quantitative whole-body autoradiography (QWBA) and liver-to-plasma area under-the-curve ratio. In bile duct cannulated rats, the primary biliary metabolite was a glucuronide. Owing to ethical concerns, it is difficult to assess liver enrichment in humans, and a lack of in vitro and in vivo correlation of glucuronidation has been reported. The current study was conducted to verify whether a hepatocyte model, rat HepatoPac, could overcome some of these limitations and provide validity for follow-up studies with human HepatoPac. With rat HepatoPac, liver enrichment values averaged 34-fold and were consistent with rat QWBA (26.8-fold) and in vivo data (42-fold). In contrast, liver enrichment in suspended hepatocytes was only 2.8-fold. Furthermore, the extent of faldaprevir glucuronidation in HepatoPac studies was in agreement with in vivo results, with glucuronidation as the major pathway (96%). Suspended rat hepatocytes did not generate the glucuronide or two key hydroxylated metabolites that were observed in vivo. Overall, our studies suggest that HepatoPac is a promising in vitro model to predict in vivo liver enrichment and metabolism, especially for glucuronidation, and has demonstrated superiority over suspended hepatocytes.
Asunto(s)
Antivirales/metabolismo , Glucurónidos/metabolismo , Hepacivirus/efectos de los fármacos , Hepatocitos/efectos de los fármacos , Hígado/metabolismo , Oligopéptidos/metabolismo , Tiazoles/metabolismo , Ácidos Aminoisobutíricos , Animales , Antivirales/farmacocinética , Bilis/metabolismo , Transporte Biológico , Biotransformación , Células Cultivadas , Técnicas de Cocultivo , Criopreservación , Medios de Cultivo , Relación Dosis-Respuesta a Droga , Estabilidad de Medicamentos , Fibroblastos/citología , Hepatocitos/citología , Hepatocitos/metabolismo , Leucina/análogos & derivados , Masculino , Tasa de Depuración Metabólica , Estructura Molecular , Oligopéptidos/farmacocinética , Prolina/análogos & derivados , Quinolinas , Ratas , Ratas Long-Evans , Ratas Sprague-Dawley , Tiazoles/farmacocinéticaRESUMEN
Hepatitis C virus (HCV) infection is a serious cause of chronic liver disease worldwide with more than 170 million infected individuals at risk of developing significant morbidity and mortality. Current interferon-based therapies are suboptimal especially in patients infected with HCV genotype 1, and they are poorly tolerated, highlighting the unmet medical need for new therapeutics. The HCV-encoded NS3 protease is essential for viral replication and has long been considered an attractive target for therapeutic intervention in HCV-infected patients. Here we identify a class of specific and potent NS3 protease inhibitors and report the evaluation of BILN 2061, a small molecule inhibitor biologically available through oral ingestion and the first of its class in human trials. Administration of BILN 2061 to patients infected with HCV genotype 1 for 2 days resulted in an impressive reduction of HCV RNA plasma levels, and established proof-of-concept in humans for an HCV NS3 protease inhibitor. Our results further illustrate the potential of the viral-enzyme-targeted drug discovery approach for the development of new HCV therapeutics.